Physician profile
Michael B Rodricks
NPI 1497732879
$6,460.74
in general payments reported to CMS, 2019-2025
21 companies · $432 in 2025
The $432 reported for 2025 was more than what 82% of Critical Care Medicine (Anesthesiology) providers received nationally (typical 2025 total: $97.90).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $468 · 2021: $1,296 · 2022: $1,071 · 2023: $1,111 · 2024: $890 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.25 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $1,771.69 | 2021-2025 | Giapreza |
| Astrazeneca Pharmaceuticals Lp | $1,284.40 | 2020-2024 | Andexxa, Farxiga |
| Allergan, INC. | $760.64 | 2019-2020 | |
| Csl Behring | $515.93 | 2019-2025 | Kcentra, Haegarda |
| Portola Pharmaceuticals, LLC | $332.80 | 2019-2020 | |
| Shionogi INC | $326.47 | 2023-2024 | Fetroja |
| Ambu INC. | $308.43 | 2022 | |
| Abbvie INC. | $304.32 | 2021-2024 | Avycaz |
| Chiesi USA, INC. | $141.76 | 2022-2025 | Cleviprex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.91 | 2021-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $114.23 | 2019 | |
| Gilead Sciences, INC. | $96.75 | 2021-2022 | |
| Mindray Ds USA, INC. | $96.03 | 2023-2024 | Te7 Max, Te X |
| Pfizer INC. | $81.33 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.92 | 2023 | Lifevest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $37.54 | 2024-2025 | Fisher & Paykel Healthcare |
| Alexion Pharmaceuticals, INC. | $32.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.28 | 2019 | |
| Merck Sharp & Dohme LLC | $18.31 | 2023 | Bridion |
| Abiomed | $16.09 | 2025 | |
| Avanos Medical | $14.35 | 2024 | On-Q* Pump and Accessories |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rodricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.